Organization (Industry)
VANTIVE HEALTH LLC
ClinicalTrials.gov lists VANTIVE HEALTH LLC as lead sponsor of 55 trials. It has 21 active development programs and 7 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 7 registered with a 2026 start date. The dashed outline is the pace from the 7 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers VANTIVE HEALTH LLC: 55 lead-sponsored trials and 2 legal-entity registrations.
Disease areas (24)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Renal Insufficiency, Chronic | 34 |
| Kidney Failure, Chronic | 30 |
| Acute Kidney Injury | 10 |
| Inflammation | 7 |
| Sepsis | 4 |
Showing 5 of 24 disease areas.
Trials by start year as sponsor or collaborator (24)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2026 (partial year) | 7 |
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 1 |
| 2022 | 1 |
| 2021 | 2 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 1 |
| 2016 | 2 |
Showing 10 of 24 years.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (21)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Prismocitrate 18 | Acute Kidney Injury | Phase 3 | 2 |
| Experimental Peritoneal Dialysis Solution | Kidney Failure, Chronic | Phase 3 | 2 |
| Experimental Peritoneal Dialysis Solution | Renal Insufficiency, Chronic | Phase 3 | 2 |
| No anticoagulation | Acute Kidney Injury | Phase 3 | 1 |
| Dianeal, Extraneal, Nutrineal | Diabetes Mellitus | Phase 3 | 1 |
Showing 5 of 21 active programs.
Approved assets (7)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Icodextrin | 3 |
| Dianeal | 3 |
| Physioneal | 2 |
| Peritoneal Dialysis treatment (no specific drug is defined) | 2 |
| Nutrineal | 2 |
Showing 5 of 7 approved assets.
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 80% hit target (n=10) | 20% on time (n=10) |
Journals published in (35)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association | 8 |
| Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis | 4 |
| The Cochrane database of systematic reviews | 4 |
| ASAIO journal (American Society for Artificial Internal Organs : 1992) | 3 |
| Artificial organs | 3 |
Showing 5 of 35 journals.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 3 |
FDA recalls (12)
Shown in this order: most recent first.
| Product | Classification | Initiated |
|---|---|---|
| PRISMAFLEX ST100 SET US, Product Code 107636US; Dialyzer, High Permeability With Or Without Sealed Dialysate System | Class II | 2026-01-06 |
| PRISMAFLEX ST150 SET US, Product Code 107640US; Dialyzer, High Permeability With Or Without Sealed Dialysate System | Class II | 2026-01-06 |
| OXIRIS SET, Product Code 112016; Dialyzer, High Permeability With Or Without Sealed Dialysate System | Class II | 2026-01-06 |
| PRIMSAFLEX M100 SET, Product Code 106697; Dialyzer, High Permeability With Or Without Sealed Dialysate System | Class II | 2026-01-06 |
| PRISMAFLEX M150 SET, Product Code 109990; Dialyzer, High Permeability With Or Without Sealed Dialysate System | Class II | 2026-01-06 |
Showing 5 of 12 recalls.
FDA import refusals (1)
| Refused import lines | Latest refusal |
|---|---|
| 1 | 2025-05-28 |
Manufacturing and distribution sites (2)
Shown in this order: severity rank then name.
| Facility | Location | Regulators | Member organization |
|---|---|---|---|
| Vantive US Healthcare LLC | Deerfield, US | FDA | |
| Vantive US Healthcare LLC | Deerfield, US | FDA |
Organization relationships (6)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Baxter Healthcare Corporation | Co sponsors trial with | 2 |
| Baxter International Inc | Co sponsors trial with | 1 |
| The University of Sydney | Co sponsors trial with | 1 |
| Pusan National University Yangsan Hospital | Co sponsors trial with | 1 |
| Berry Consultants, LLC (United States) | Co sponsors trial with | 1 |
Showing 5 of 6 relationships.
Latest dated events (78)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-07-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-06-17 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-04-05 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2026-03-01 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 78 events.
Biomarker capability evidence (61)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| ALB | Trial sponsor | Named in trial inclusion criteria |
| BTBD8 | Trial sponsor | Named in trial inclusion criteria |
| CRP | Trial sponsor | Named in trial inclusion criteria |
| EMP1 | Trial sponsor | Primary endpoint in a Phase 3 trial |
| EPO | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 61 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, related companies not grouped here, us granted patents, sec-reported annual financials, financing and grant events, fda warning letters, fda untitled letters, climate targets, as filed, workforce and board diversity, as filed, clia clinical laboratory certificates, and biomarkers this organization publishes on.